Stockscreener 앱 받기
30.00
1.90%
0.56
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Trading (CRNX) With Integrated Risk Controls - news.stocktradersdaily.com
Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan
Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha
Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Research Analysts Offer Predictions for CRNX FY2026 Earnings - Defense World
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
(CRNX) Trading Report - news.stocktradersdaily.com
Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India
(CRNX) Investment Report - news.stocktradersdaily.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 | CRNX Stock News - GuruFocus
Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
BNP Paribas Financial Markets Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - Yahoo Finance
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation? - Yahoo Finance
CRNX Achieves FDA Orphan Drug Status for Paltusotine in Carcinoi - GuruFocus
Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - MSN
Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - The Manila Times
New Clinical Data: Oral Drug Paltusotine Could Replace Injectable Acromegaly TreatmentsKey AACE 2025 Findings - Stock Titan
Analysts Set Expectations for CRNX FY2025 Earnings - Defense World
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and Pivotal Launches on the Horizon - GuruFocus
Earnings call transcript: Crinetics Pharma stock rises after Q1 2025 results - Investing.com Nigeria
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics (CRNX) Exceeds Revenue Expectations, Advances Key Proj - GuruFocus
Crinetics Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $0.4M, EPS Misses at -$1.04 - GuruFocus
Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position - Nasdaq
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus
Viracta Therapeutics (NASDAQ:VIRX) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Review - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings - GuruFocus
Closing Figures: Crinetics Pharmaceuticals Inc (CRNX)’s Negative Finish at 30.52, Down -9.30 - DWinneX
August 15th Options Now Available For Crinetics Pharmaceuticals (CRNX) - Nasdaq
0.34%
7.69%
자본화:
|
볼륨(24시간):